1. Allagio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia, 2022; 6: 1720–1748.
2. Arber DA, Orazi A, Hasserjian RP, et al. The international consensus classification of myeloid neoplasms and acute leukemias: Integrating morphological, clinical and genomic data. Blood, 2022 Sep 15;140(11): 1200–1228.
3. Bene MC, Bernier M, Casasnovas RO, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. European Group for the Immunological Classification of Leukemias (EGIL). Blood, 1998; 92 (2): 596–599.
4. Bornhäuser M, Schliemann C, Schetelig J, et al. Allogeneic hematopoietic cell transplantation in patients ≤ 60 years with intermediate-risk acute myeloid leukemia in first remission – results of the randomized trial. Blood, 2021; 138 (Supp. 1): 173.
5. Burchert A, Bug G, Fritz L, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol, 2020; 38: 2993–3002.